Drug Trial Radar · NCT02467335
Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Sep 25, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
52
Actual
Start
Jan 29, 2015
Primary completion
Oct 3, 2015
Study completion Oct 3, 2015
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- GlaxoSmithKline
- First posted
- Jun 10, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A single oral dose study in subjects with hepatic impairment and healthy control subjects. Subjects will stay at the clinical facility where interval blood samplings will be obtained and examined for drug effect.
Conditions
- Infection, Human Immunodeficiency Virus
Interventions
BMS-663068Drug
BMS-663068
Primary outcomes
What the sponsor says the trial is designed to measure.
- The effects of hepatic impairment on the single-dose peak plasma concentration Cmax of BMS-626529 (metabolite).Time frame: 5 days
- The effects of hepatic impairment on the single-dose area under the plasma concentration versus time curve AUC (INF) of BMS-626529 (metabolite).Time frame: 5 days
- The effects of hepatic impairment on the single-dose area under the plasma concentration versus time curve AUC (0-T) of BMS-626529 (metabolite).Time frame: 5 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Hamilton, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.